Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
1.440
+0.010 (0.70%)
Feb 21, 2025, 4:00 PM EST - Market closed
SONN Employees
Sonnet BioTherapeutics Holdings had 13 employees as of September 30, 2024. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
$76,923
Profits / Employee
-$725,341
Market Cap
4.41M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
SONN News
- 3 days ago - Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates - GlobeNewsWire
- 4 days ago - Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - GlobeNewsWire
- 9 days ago - Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer - GlobeNewsWire
- 9 days ago - Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update - GlobeNewsWire
- 25 days ago - Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology - GlobeNewsWire
- 4 weeks ago - Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewsWire
- 4 weeks ago - Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - GlobeNewsWire
- 2 months ago - Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - GlobeNewsWire